[{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$33.1 million","upfrontCash":"Undisclosed","newsHeadline":"Enthera Pharmaceuticals Raises \u20ac28 Million in Series A Financing to Advance Restorative Therapy for Type 1 Diabetes and IBD","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Roche Venture Fund","pharmaFlowCategory":"D","amount":"$42.3 million","upfrontCash":"Undisclosed","newsHeadline":"Enthera Pharmaceuticals Extends Series A Financing, Raising a Total Of \u20ac35m","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enthera Pharmaceuticals Initiates Phase 1 Clinical Trial with Lead Candidate Ent001","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"ITALY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Enthera Pharmaceuticals
Ent001 targets the TMEM219 ligand, IGFBP3, it is designed to bind to TMEM219 and prevent cell death and the inflammation in type 1 diabetes and several other autoimmune diseases.
The proceeds from the Series A financing will be used to obtain clinical proof-of-concept through a first-in-human study of Ent001, Enthera’s lead candidate.
Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastrointestinal diseases and progress pipeline assets.